AbbVie Inc. (ABBV)
Stock Price Chart
Key Info
| Market Cap | 152.18B |
| Revenue (ttm) | 36.23B |
| Net Income (ttm) | 6.96B |
| Shares Out | 1.76B |
| EPS (ttm) | 4.52 |
| PE Ratio | 19.08 |
| Forward PE | 7.07 |
| Dividend | $4.72 |
| Dividend Yield | 5.47% |
Stock Quote
| Trading Day | Sep 25, 2020 |
| Last Price | $86.23 |
| Previous Close | $85.91 |
| Change ($) | 0.32 |
| Change (%) | 0.37% |
| Day's Open | 85.98 |
| Day's Range | 85.46 - 86.86 |
| Day's Volume | 9,935,566 |
| 52-Week Range | 62.55 - 101.28 |
More Stats
| Market Cap | 152.18B |
| Enterprise Value | 233.57B |
| Earnings Date (est) | Oct 30, 2020 |
| Ex-Dividend Date | Jul 14, 2020 |
| Shares Outstanding | 1.76B |
| Float | 1.76B |
| EPS (basic) | 4.72 |
| EPS (diluted) | 4.52 |
| FCF / Share | 8.57 |
| Dividend | $4.72 |
| Dividend Yield | 5.47% |
| Earnings Yield | 5.24% |
| FCF Yield | 9.28% |
| Payout Ratio | n/a |
| Shares Short | 13.28M |
| Short Ratio | 1.82 |
| Short % of Float | 0.75% |
| Beta | 0.72 |
| PE Ratio | 19.08 |
| Forward PE | 7.07 |
| P/FCF Ratio | 10.78 |
| PS Ratio | 4.20 |
| PB Ratio | 10.31 |
| Revenue | 36.23B |
| Operating Income | 10.93B |
| Net Income | 6.96B |
| Free Cash Flow | 14.12B |
| Net Cash | -81.39B |
| Net Cash / Share | -46.12 |
| Gross Margin | 71.29% |
| Operating Margin | 30.17% |
| Profit Margin | 19.20% |
| FCF Margin | 38.96% |
| ROA | 8.23% |
| ROE | 225.62% |
| ROIC | 14.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33,266 | 32,753 | 28,216 | 25,638 | 22,859 | 19,960 | 18,790 | 18,380 | 17,444 | 15,638 |
| Revenue Growth | 1.57% | 16.08% | 10.06% | 12.16% | 14.52% | 6.23% | 2.23% | 5.37% | 11.55% | - |
| Gross Profit | 25,827 | 25,035 | 21,174 | 19,806 | 18,359 | 15,534 | 14,209 | 13,872 | 12,805 | 11,345 |
| Operating Income | 12,983 | 6,383 | 9,545 | 9,340 | 7,537 | 3,411 | 5,664 | 5,817 | 3,620 | 4,717 |
| Net Income | 7,882 | 5,687 | 5,309 | 5,953 | 5,144 | 1,774 | 4,128 | 5,275 | 3,433 | 4,178 |
| Shares Outstanding | 1,481 | 1,541 | 1,596 | 1,622 | 1,625 | 1,595 | 1,589 | 1,577 | 1,577 | - |
| Earnings Per Share | 5.28 | 3.66 | 3.30 | 3.63 | 3.13 | 1.10 | 2.56 | 3.35 | 2.18 | 2.65 |
| EPS Growth | 44.26% | 10.91% | -9.09% | 15.97% | 184.55% | -57.03% | -23.58% | 53.67% | -17.74% | - |
| Dividend Per Share | 4.28 | 3.59 | 2.56 | 2.28 | 2.02 | 1.66 | 1.60 | - | - | - |
| Dividend Growth | 19.22% | 40.23% | 12.28% | 12.87% | 21.69% | 3.75% | - | - | - | - |
| Operating Cash Flow | 13,324 | 13,427 | 9,960 | 7,041 | 7,535 | 3,549 | 6,267 | 6,345 | 6,247 | 4,976 |
| Capital Expenditures | -552 | -638 | -529 | -479 | -532 | -612 | -491 | -333 | -356 | -448 |
| Free Cash Flow | 12,772 | 12,789 | 9,431 | 6,562 | 7,003 | 2,937 | 5,776 | 6,012 | 5,891 | 4,528 |
| Cash & Equivalents | 39,924 | 8,061 | 9,789 | 6,423 | 8,407 | 8,374 | 9,895 | 7,976 | 653 | 1,883 |
| Total Debt | 66,728 | 40,310 | 37,368 | 36,842 | 31,671 | 14,977 | 14,723 | 15,672 | 48.00 | - |
| Net Cash / Debt | -26,804 | -32,249 | -27,579 | -30,419 | -23,264 | -6,603 | -4,828 | -7,696 | 605 | 1,883 |
| Assets | 89,115 | 59,352 | 70,786 | 66,099 | 53,050 | 27,513 | 29,198 | 27,008 | 19,521 | 21,135 |
| Liabilities | 97,287 | 67,798 | 65,689 | 61,463 | 49,105 | 25,771 | 24,706 | 23,645 | 7,589 | 5,432 |
| Book Value | -8,172 | -8,446 | 5,097 | 4,636 | 3,945 | 1,742 | 4,492 | 3,363 | 11,932 | 15,703 |
Company Profile
Company Details
| Full Name | AbbVie Inc. |
| Country | United States |
| Employees | 47,000 |
| CEO | Richard A. Gonzalez |
Stock Information
| Ticker Symbol | ABBV |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NYSE: ABBV |
Description
AbbVie discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.